Literature DB >> 17576838

Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Joseph Meletiadis1, Charalampos Antachopoulos, Theodouli Stergiopoulou, Spyros Pournaras, Emmanuel Roilides, Thomas J Walsh.   

Abstract

Antifungal agents may differ in their fungicidal activities against Aspergillus spp. In order to compare the fungicidal activities of voriconazole and amphotericin B against 40 isolates of Aspergillus fumigatus, A. flavus, and A. terreus, we developed a new microbroth colorimetric method for assessing fungicidal activities and determining minimal fungicidal concentrations (MFCs). This methodology follows the antifungal susceptibility testing reference method M-38A for MIC determination. After drug removal and addition of fresh medium, growth of viable conidia adhering to the bottoms of the microtitration wells was assessed by a colorimetric assay of metabolic activity after 24 h of incubation. The new method was faster (six times), reproducible (92 to 97%), and in agreement with culture-based MFCs (91 to 100%). Differential fungicidal activities of voriconazole and amphotericin B were found among the three Aspergillus species, with A. fumigatus and A. flavus having the lowest (1 and 2 mg/liter, respectively) and A. terreus the highest (>16 mg/liter) median amphotericin B MFCs; A. flavus had a lower median voriconazole MFC (4 mg/liter) than the other species (>8 mg/liter; P < 0.05). Amphotericin B was fungicidal (MFC/MIC </= 4) against all A. fumigatus and A. flavus isolates but no A. terreus isolates, whereas voriconazole was fungicidal against 82% of A. flavus isolates and fungistatic (MFC/MIC > 4) against 94% of A. fumigatus and 84% of A. terreus isolates. The new methodology revealed a concentration-dependent sigmoid pattern of fungicidal effects, indicating that fungicidal activity is not an all-or-nothing phenomenon and that some degree of fungicidal action can be found even for agents considered fungistatic based on the MFC/MIC ratio.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576838      PMCID: PMC2043246          DOI: 10.1128/AAC.00345-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole.

Authors:  A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  J Antimicrob Chemother       Date:  2006-12-21       Impact factor: 5.790

5.  Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.

Authors:  P H Chandrasekar; J Cutright; E Manavathu
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

6.  Colorimetric assay for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; A Fothergill; J Peter; M G Rinaldi; T J Walsh
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

8.  Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

Authors:  Thomas J Walsh; Vidmantas Petraitis; Ruta Petraitiene; Aida Field-Ridley; Deanna Sutton; Mahmoud Ghannoum; Tin Sein; Robert Schaufele; Joanne Peter; John Bacher; Heather Casler; Derek Armstrong; Anna Espinel-Ingroff; Michael G Rinaldi; Caron A Lyman
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

9.  Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; V Chaturvedi; A Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.

Authors:  P A Warn; G Morrissey; J Morrissey; D W Denning
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

View more
  27 in total

1.  Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Joseph Meletiadis; Rafal Al-Saigh; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides; Loukia Zerva
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 2.  Emerging threat of triazole-resistant Aspergillus fumigatus.

Authors:  Jeffrey M Rybak; Jarrod R Fortwendel; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790

3.  A murine model of cutaneous aspergillosis for evaluation of biomaterials-based local delivery therapies.

Authors:  Alexander M Tatara; Emma Watson; Nathaniel D Albert; Panayiotis D Kontoyiannis; Dimitrios P Kontoyiannis; Antonios G Mikos
Journal:  J Biomed Mater Res A       Date:  2019-04-07       Impact factor: 4.396

Review 4.  Antifungal drug development: challenges, unmet clinical needs, and new approaches.

Authors:  Terry Roemer; Damian J Krysan
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

5.  In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of Aspergillus terreus sensu stricto.

Authors:  Mariana S Fernández; Florencia D Rojas; María E Cattana; María de Los Ángeles Sosa; Cristina A Iovannitti; Cornelia Lass-Flörl; Gustavo E Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.

Authors:  Emily E Rosowski; Jiaye He; Jan Huisken; Nancy P Keller; Anna Huttenlocher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 7.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

8.  Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Rafal Al-Saigh; Maria Siopi; Nikolaos Siafakas; Aristea Velegraki; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

9.  Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum.

Authors:  Antigoni Elefanti; Johan W Mouton; Katerina Krompa; Rafal Al-Saigh; Paul E Verweij; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

10.  Invasive mold infections following combat-related injuries.

Authors:  Tyler Warkentien; Carlos Rodriguez; Bradley Lloyd; Justin Wells; Amy Weintrob; James R Dunne; Anuradha Ganesan; Ping Li; William Bradley; Lakisha J Gaskins; Françoise Seillier-Moiseiwitsch; Clinton K Murray; Eugene V Millar; Bryan Keenan; Kristopher Paolino; Mark Fleming; Duane R Hospenthal; Glenn W Wortmann; Michael L Landrum; Mark G Kortepeter; David R Tribble
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.